Diadema Partners LP Takes $351,000 Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Diadema Partners LP bought a new position in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 42,081 shares of the company's stock, valued at approximately $351,000. Diadema Partners LP owned 0.08% of Zevra Therapeutics at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in Zevra Therapeutics by 2.5% in the 4th quarter. Vanguard Group Inc. now owns 2,824,212 shares of the company's stock valued at $23,554,000 after buying an additional 68,151 shares in the last quarter. Altium Capital Management LLC raised its holdings in Zevra Therapeutics by 8.8% during the 4th quarter. Altium Capital Management LLC now owns 1,850,000 shares of the company's stock worth $15,429,000 after purchasing an additional 150,000 shares during the last quarter. Geode Capital Management LLC grew its holdings in Zevra Therapeutics by 13.8% during the 4th quarter. Geode Capital Management LLC now owns 1,188,120 shares of the company's stock worth $9,912,000 after acquiring an additional 144,256 shares during the period. AIGH Capital Management LLC acquired a new position in Zevra Therapeutics in the fourth quarter valued at about $6,577,000. Finally, State Street Corp grew its holdings in Zevra Therapeutics by 7.4% during the third quarter. State Street Corp now owns 772,825 shares of the company's stock valued at $5,363,000 after purchasing an additional 52,966 shares during the period. 35.03% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

ZVRA has been the topic of several research reports. JMP Securities set a $18.00 target price on Zevra Therapeutics in a research note on Wednesday, March 12th. Citigroup restated an "outperform" rating on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $25.00 target price on shares of Zevra Therapeutics in a report on Wednesday, March 12th. Canaccord Genuity Group boosted their target price on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the company a "buy" rating in a research report on Thursday, March 13th. Finally, HC Wainwright restated a "buy" rating and set a $20.00 price objective on shares of Zevra Therapeutics in a research note on Thursday, March 13th. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $22.29.

Insider Transactions at Zevra Therapeutics

In related news, Director John B. Bode purchased 10,000 shares of the firm's stock in a transaction that occurred on Wednesday, March 19th. The shares were purchased at an average cost of $7.96 per share, with a total value of $79,600.00. Following the purchase, the director now owns 40,000 shares of the company's stock, valued at $318,400. This represents a 33.33 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO R. Laduane Clifton sold 11,000 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $86,460.00. Following the sale, the chief financial officer now owns 51,361 shares of the company's stock, valued at $403,697.46. This represents a 17.64 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 85,773 shares of company stock valued at $674,176. 2.40% of the stock is currently owned by company insiders.

Zevra Therapeutics Stock Down 0.6 %

ZVRA stock traded down $0.04 on Friday, reaching $7.20. 381,265 shares of the company traded hands, compared to its average volume of 610,289. Zevra Therapeutics, Inc. has a one year low of $4.20 and a one year high of $9.76. The firm has a fifty day simple moving average of $7.53 and a 200-day simple moving average of $8.13. The company has a market cap of $393.69 million, a P/E ratio of -3.65 and a beta of 1.94. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last announced its earnings results on Tuesday, March 11th. The company reported ($0.67) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.28). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The business had revenue of $12.00 million for the quarter, compared to analysts' expectations of $8.93 million. Research analysts anticipate that Zevra Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.